Search research articles
Contact Us
Filters
Showing results (291-300 of 344) with videos related to
Page
of 35
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
February 18, 2014
EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?
L E L Hendriks, E F Smit, B A H Vosse, et al.
ESMO Open
|
November 18, 2025
Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50
A De Giglio, L Zullo, A Di Federico, et al.
JAMA Network Open
|
February 3, 2026
Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer: A Systematic Review and Meta-Analysis
Jonas Willmann, Camilla von Wachter, Ronja Zehnder, et al.
Human Reproduction (Oxford, England)
|
August 29, 2014
How long should we continue clomiphene citrate in anovulatory women?
N S Weiss, S Braam, T E König, et al.
Targeted Oncology
|
June 5, 2025
Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib
Fenneke Zwierenga, M Benthe Muntinghe-Wagenaar, Pim Rozendal, et al.
Cancer Chemotherapy and Pharmacology
|
November 6, 2025
Optimizing lazertinib therapy through GSTM1 genotyping: a strategy to reduce excess drug exposure and potential toxicity
Rob Ter Heine, Bianca J C van den Bosch, Robin M van Geel, et al.
FEBS Letters
|
December 31, 1997
Proteolytic processing of presenilin-1 (PS-1) is not associated with Alzheimer's disease with or without PS-1 mutations
M Okochi, K Ishii, M Usami, et al.
The Oncologist
|
May 9, 2023
Prevalence and Predictors of Physician-Patient Discordance in Prognostic Perceptions in Advanced Cancer
Naomi Cornelia Anna van der Velden, Paul K J Han, Hanneke W M van Laarhoven, et al.
JTO Clinical and Research Reports
|
April 10, 2023
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target <i>HER2</i> Bypass Track Resistance in <i>EGFR</i> Mutation-Positive NSCLC
M Jebbink, A J de Langen, K Monkhorst, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 31, 2025
Effect of treatment sequencing on outcome of patients with non-small cell lung cancer with a synchronous solitary extrathoracic metastasis
Mandy Jongbloed, Ronald A M Damhuis, Wouter H Van Geffen, et al.
Page
of 35
Search research articles
Search
Showing results (291-300 of 344) with videos related to
Sort By:
Page
of 35
Lung Cancer (Amsterdam, Netherlands)
|
February 18, 2014
EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?
L E L Hendriks, E F Smit, B A H Vosse, et al.
ESMO Open
|
November 18, 2025
Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50
A De Giglio, L Zullo, A Di Federico, et al.
JAMA Network Open
|
February 3, 2026
Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer: A Systematic Review and Meta-Analysis
Jonas Willmann, Camilla von Wachter, Ronja Zehnder, et al.
Human Reproduction (Oxford, England)
|
August 29, 2014
How long should we continue clomiphene citrate in anovulatory women?
N S Weiss, S Braam, T E König, et al.
Targeted Oncology
|
June 5, 2025
Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib
Fenneke Zwierenga, M Benthe Muntinghe-Wagenaar, Pim Rozendal, et al.
Cancer Chemotherapy and Pharmacology
|
November 6, 2025
Optimizing lazertinib therapy through GSTM1 genotyping: a strategy to reduce excess drug exposure and potential toxicity
Rob Ter Heine, Bianca J C van den Bosch, Robin M van Geel, et al.
FEBS Letters
|
December 31, 1997
Proteolytic processing of presenilin-1 (PS-1) is not associated with Alzheimer's disease with or without PS-1 mutations
M Okochi, K Ishii, M Usami, et al.
The Oncologist
|
May 9, 2023
Prevalence and Predictors of Physician-Patient Discordance in Prognostic Perceptions in Advanced Cancer
Naomi Cornelia Anna van der Velden, Paul K J Han, Hanneke W M van Laarhoven, et al.
JTO Clinical and Research Reports
|
April 10, 2023
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target <i>HER2</i> Bypass Track Resistance in <i>EGFR</i> Mutation-Positive NSCLC
M Jebbink, A J de Langen, K Monkhorst, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 31, 2025
Effect of treatment sequencing on outcome of patients with non-small cell lung cancer with a synchronous solitary extrathoracic metastasis
Mandy Jongbloed, Ronald A M Damhuis, Wouter H Van Geffen, et al.
Page
of 35